Please login to the form below

What is everyone ‘ARPAing on about?

On Wednesday 16th September, Ursula Von Der Leyen, President of the European Union, announced in her State of Union address that they plan to develop BARDA, a Biomedical Advanced Research and Development Agency. This follows on from the Conservative Government pledging in their manifesto in late 2019 to develop ARPA, the Advanced Research Projects Agency. Both of these agencies are direct descendants of DARPA, the Defense Advanced Research Projects Agency founded in the USA in 1958 to create “Nation technology-based options for preventing – and creating - technological surprise.” Technological surprise is a wonderfully euphemistic phrase which refers to military “surprise” in the context of the Cold War. However, in the context of a global pandemic and the politicisation of the race to find a vaccine many are now drawing Cold War comparisons. But can DARPA, ARPA or BARDA actually deliver technological surprise? Jennifer Blainey, Director, Hanover Health explores.

The author of the Policy Exchange paper on ARPA published earlier this year warned “The government should not, however, underestimate the difficulty of this venture: efforts to create DARPA analogs, both within the USG and in allied countries abroad are, thus far, ‘unblemished by success’.”1

This question goes to the very heart of how innovation occurs. Many industries reliant on innovation had bought into the idea of creative clusters prior to the pandemic. Kings Cross in London was becoming an exciting creative cluster of science, technology and art with Google, St Martin’s Art School and pharma companies all in close proximity hoping to benefit from these different disciplines existing in close proximity. But then we all had to start working from home.

Professor Terence Kealey who wrote a paper “No to ARPA” for the Adam Smith Institute claims it was the defunding of DARPA which actually created the Silicon Valley we are so in thrall today. “The newly redundant scientists streamed out to the Xerox Palo Alto Research Center, where they invented the likes of the mouse, laser printer and the Ethernet network”.2

So who’s right? Do taxpayers need to fund an agency to develop the technological surprises of tomorrow? Or do the scientists need to be free to roam in the private sector and respond to real world commercial opportunities?

Perhaps a sort of answer lies in a paper produced by Rand in 1964 which sought to make predictions about the future. It looked ahead to the year 1984 and 2000. It predicted that advances in automation would lead to social upheaval and we would be mining the moon. What it didn’t predict was the mobile smart phone. It's impossible to predict the future, but what helped to create the world after 1964 was increasing collaboration between scientists, engineers and creatives of all types for commercial reasons rather than national policy interests. Maybe what we today need is GARPA?

1. https://policyexchange.org.uk/wp-content/uploads/Visions-of-Arpa.pdf
2. https://www.thetimes.co.uk/article/copying-us-defence-research-agency-is-a-waste-of-money-ds25vfgd6

6th October 2020

Share

Company Details

Hanover Communications

+44 (0)20 7400 4480

Contact Website

Address:
70 Gray's Inn Road
London
WC1X 8BT
United Kingdom

Latest content on this profile

What does the COVID-19 vaccine mean for the future of R&D?
Amid a pandemic, time is a luxury the world cannot afford. The last 12 months have contradicted what we once thought about the speed of progressing scientific research. Here Shannon Lacombe explores the factors that have contributed to the unprecedented speed of vaccine development from early-stage research to mass public rollout. She also looks at what precedent this has set for the future of research and development timelines and the assumptions and status quo that will now be challenged as a result.
Hanover Communications
Is the world ready for a COVID-19 vaccine?
At the beginning of November, Pfizer and BioNTech announced that their vaccine candidate was more than 90% effective at preventing COVID-19 infection. Since then, other good news has followed, with collaborations, including Moderna and AstraZeneca, publishing similarly positive results. This is a phenomenal feat that would have been unimaginable just one year ago. But a vaccine is only as effective as its deployment and uptake. There should be no doubt that as soon as the first COVID-19 vaccine was approved, a very difficult logistics game ensued. The reality is that a COVID-19 vaccine will present a whole new unfamiliar set of operational challenges. There are currently more than 170 candidate vaccines in development, each with its own benefits and each with its own challenges. Here, we explore some of those challenges and reflect on what must be considered by health systems and governments to set us on track towards pandemic recovery.
Hanover Communications
It's out - so what?
The European Commission’s Pharmaceutical Strategy has been published and the Commission has presented its priorities for the coming years. The focus is on patient access to affordable treatments; ensuring and boosting the competitiveness of the European pharmaceutical sector and making sure that the EU will have a strong voice on global health and pharmaceutical policy. Stakeholders now need to make sure that their voices are heard and included in upcoming proposals and, eventually, in legislation. By Jenni Kortelainen, Hanover EU
Hanover Communications
Let's be ambitious for patients and life sciences investment in Global Britain
“Take up of new medicines in the UK continues to be slow by international standards”. Since this Pharmaceutical Industry Competitiveness Task Force report in 2005, there have been at least five UK life science strategies plus three PPRS or VPAS deals. All have promised to accelerate access of new medicines to patients. Sadly, 12 years on, the 2017 Life Sciences Industrial Strategy could only restate the challenge: “Evidence demonstrates that access to and diffusion of products in the NHS is often slower than in some comparable countries”. Can we ever break this cycle? By Andrew Harrison, Group Managing Director of Hanover Health.
Hanover Communications
What is everyone ‘ARPAing on about?
On Wednesday 16th September, Ursula Von Der Leyen, President of the European Union, announced in her State of Union address that they plan to develop BARDA, a Biomedical Advanced Research and Development Agency. This follows on from the Conservative Government pledging in their manifesto in late 2019 to develop ARPA, the Advanced Research Projects Agency. Both of these agencies are direct descendants of DARPA, the Defense Advanced Research Projects Agency founded in the USA in 1958 to create “Nation technology-based options for preventing – and creating - technological surprise.” Technological surprise is a wonderfully euphemistic phrase which refers to military “surprise” in the context of the Cold War. However, in the context of a global pandemic and the politicisation of the race to find a vaccine many are now drawing Cold War comparisons. But can DARPA, ARPA or BARDA actually deliver technological surprise? Jennifer Blainey, Director, Hanover Health explores.
Hanover Communications
Tackling obesity via green prescribing: A piece of cake or a half-baked strategy?
In our new article, Lloyd Tingley explores the wider societal and behavioural factors that will impact the success of green prescribing and the obesity strategy, and the role companies will play in driving a society wide approach that impacts infrastructure, adherence, health inequalities, and more.
Hanover Communications